In particular, when compared with platinum‐based chemotherapy, patients with high programmed death‐ligand 1 (PD‐L1) expression (PD‐L1 tumor proportion score [TPS] ≥50%) who received first‐line treatment with pembrolizumab (a programmed cell death protein‐1 [PD‐1] inhibitor and humanized monoclonal antibody) as either monotherapy (MONO) or combined with chemotherapy (COMB) demonstrated improved progression‐free survival (PFS) and overall survival (OS).1, 2, 3, 4, 5. This evidence concerns the gene CD274 and neoplasm.